GENE ONLINE|News &
Opinion
Blog

2022-01-04| Technology

Scientists to Study the Effect of Microgravity on Human Brain Cells in Space

by Ameya Paleja
Share To

In an attempt to further understand the effects of gravity on the function of the brain, scientists are sending an in vitro neurovascular model of the human brain to the International Space Station (ISS), a press release from the providers of the in vitro model said. The ISS provides a microgravity environment where the effects of gravity can be isolated on the functioning of the biological tissue. 

The in vitro unit consists of five cell types of the human brain including the blood-brain barrier and is built by Emulate Inc., a Boston, Massachusetts-based company. Emulate’s Organ on a Chip technology provides in vitro models to help us further our understanding of human cell function and hence diseases. It also provides for a better research environment for the prediction of cellular response with higher precision and detail than cell cultures and animal testing. 

“Previous studies, such as NASA’s Functional Immune study, have shown changes in endothelial cell morphology in 2D cultures in space as well as many changes in astronaut immune function during spaceflight,” said Daniel Levner, Chief Technology Officer of Emulate.“Understanding how the immune system interacts with organ biology in microgravity will be important for future research.”

Experiments on Brain Chips in Space

 

Emulate’s Brain Chip that consists of both the neuronal and vascular components of the human brain is the size of a USB thumb drive and has two fluidic channels that are separated by a porous membrane. The neuronal channel contains cortical neurons, astrocytes, pericytes, and microglia while the vascular channel is lined by microvascular endothelial cells. This setup can be used to study the blood-brain barrier and the complex interactions that take place in the environment and have a role in brain physiology and disease. It can also be used to evaluate which drugs can cross this barrier and improve our understanding of the brain response. 

For the recent mission, Emulate is sending 12 such brain chips in a shoebox-sized instrument that NASA uses for experiments at the ISS.  The instrument has all the necessary components for environment control, perfusion, fluid sampling, dosing, etc. needed for the intended experiments to be conducted in an automated fashion. “By comparing the human Brain-Chip response to an inflammatory stimulus under reduced gravity conditions versus its response back on Earth, we will be able to investigate differences in cytokine production, BBB permeability, and morphology,” Levner added. 

The experiments to be conducted at the International Space Station National Lab (ISS-NL) are part of the Tissue-Chips in Space initiative sponsored by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the press release said. 

 

Related Article: Research Endeavors in Space Biology – Are We Gearing Towards Another Biological Moonshot? – GeneOnline News

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Inside the Aging Brain: NTU Singapore’s Revelation on Memory Neuron Communication
2024-01-24
2023 ASCO Annual Meeting: Breakthroughs in Cancer Care and Advances in CAR T-cell Therapy
2023-07-11
R&D
New Effective Biodegradable Solution for Brain Cancer
2023-06-19
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top